GlaxoSmithKline Pharmaceuticals Ltd

The key equity benchmarks traded with substantial losses in early trade, supported by weak global cues. Investors will keep a close watch on the ongoing Q2 earnings season, crude oil prices and other global developments. The Nifty slipped above the 25,350 mark. All the sectoral indices on the NSE were traded in red with IT, consumer durables and PSU Bank shares declining the most. At 09:25 IST, the barometer index, the S&P BSE Sensex, declined 448.20 points or 0.54% to 82,862.81. The Nifty 50 index fell 173.75 points or 0.68% to 25,335.85. The broader market underperformed the frontline indices. The S&P BSE Mid-Cap index fell 0.96% and the S&P BSE Small-Cap index tumbled 1.18%. The market breadth was weak. On the BSE, 869 shares rose and 2,141 shares fell. A total of 147 shares were unchanged. Foreign portfolio investors (FPIs) sold shares worth Rs 3,263.21 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 5,283.91 crore in the Indian equity market on 06 November 2025, provisional data showed. Numbers to Track: The yield on India's 10-year benchmark federal paper rose 0.14% to 6,523 from the previous close of 6.514. In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 88.6550 compared with its close of 88.6300 during the previous trading session. MCX Gold futures for 5 December 2025 settlement rose 0.25% to Rs 120,911. The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.08% to 99.79. The United States 10-year bond yield fell 0.07% to 4.090. In the commodities market, Brent crude for December 2025 settlement advanced 19 cents or 0.30% to $63.57 a barrel. Stocks in Spotlight: GlaxoSmithKline Pharmaceuticals fell 1.45%. The company reported a 2% year-on-year increase in consolidated net profit to Rs 257 crore for the quarter, compared with Rs 253 crore in the same period last year. Revenue from operations declined 3.1% to Rs 980 crore from Rs 1,011 crore a year ago. Crompton Greaves Consumer Electricals declined 1.53% after the company reported a 43% year-on-year decline in consolidated net profit to Rs 71.2 crore for the quarter, compared with Rs 125 crore in the same period last year. Revenue rose 1% to Rs 1,916 crore from Rs 1,896 crore a year ago. GMM Pfaudler fell 2.81%. The company reported a sharp rise in consolidated net profit to Rs 41.4 crore for the quarter, compared with Rs 15.2 crore in the corresponding period last year. Revenue grew 12% year-on-year to Rs 902 crore from Rs 805 crore. Global Markets: Asia market declined on Friday, mirroring Wall Street's losses as renewed concerns over stretched valuations in artificial intelligence (AI) stocks weighed on sentiment. Investors across the region are now awaiting China's October trade data, expected later in the day. Media reports indicate that exports may have grown just 3% year-on-year, slowing sharply from 8.3% in September, while imports are forecast to fall 3.2% after rising 7.4% previously. The slowdown reflects weak domestic demand, prolonged pressure from the property downturn, rising job insecurity, and the fading impact of earlier consumption stimulus. On Wall Street, AI-linked stocks extended their recent declines, dragging major indices lower. The Dow Jones Industrial Average fell 398.70 points (0.84%) to 46,912.30, while the S&P 500 dropped 1.12% to 6,720.32. The Nasdaq Composite tumbled 1.9% to 23,053.99, with the Nasdaq 100 down more than 2% for the week ' its steepest decline since early April. Adding to investor unease, October layoffs surged to 153,000, nearly triple September's figure and 175% higher year-on-year, according to Challenger, Gray & Christmas. The spike in job cuts, combined with the ongoing U.S. government shutdown, now over a month old, has further clouded the outlook for the U.S. economy.Powered by Capital Market - Live

Net profit of Glaxosmithkline Pharmaceuticals rose 1.98% to Rs 257.49 crore in the quarter ended September 2025 as against Rs 252.50 crore during the previous quarter ended September 2024. Sales declined 3.05% to Rs 979.94 crore in the quarter ended September 2025 as against Rs 1010.77 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales979.941010.77 -3 OPM %34.2631.83 - PBDT368.79355.98 4 PBT351.36339.12 4 NP257.49252.50 2 Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live

Net profit of Glaxosmithkline Pharmaceuticals rose 12.44% to Rs 205.01 crore in the quarter ended June 2025 as against Rs 182.33 crore during the previous quarter ended June 2024. Sales declined 1.16% to Rs 805.17 crore in the quarter ended June 2025 as against Rs 814.65 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales805.17814.65 -1 OPM %31.2028.30 - PBDT294.50265.81 11 PBT278.98249.40 12 NP205.01182.33 12 Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals has fixed 30 May 2025 as record date for determining entitlement of members to final dividend for the financial year ended 31st March 2025. The dividend, if approved, shall be paid on or after 30 June 2025. Powered by Capital Market - Live

Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, 'Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.' The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the company's 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.Powered by Capital Market - Live

Net profit of Glaxosmithkline Pharmaceuticals rose 35.17% to Rs 262.87 crore in the quarter ended March 2025 as against Rs 194.48 crore during the previous quarter ended March 2024. Sales rose 4.79% to Rs 974.37 crore in the quarter ended March 2025 as against Rs 929.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.23% to Rs 927.58 crore in the year ended March 2025 as against Rs 589.96 crore during the previous year ended March 2024. Sales rose 8.56% to Rs 3749.21 crore in the year ended March 2025 as against Rs 3453.71 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales974.37929.80 5 3749.213453.71 9 OPM %34.2027.67 -31.4026.31 - PBDT373.29286.32 30 1321.981029.48 28 PBT358.57268.22 34 1255.19959.80 31 NP262.87194.48 35 927.58589.96 57 Powered by Capital Market - Live

Net profit of Glaxosmithkline Pharmaceuticals rose 34.73% to Rs 260.14 crore in the quarter ended March 2025 as against Rs 193.08 crore during the previous quarter ended March 2024. Sales rose 6.06% to Rs 966.08 crore in the quarter ended March 2025 as against Rs 910.87 crore during the previous quarter ended March 2024. For the full year,net profit rose 57.19% to Rs 919.06 crore in the year ended March 2025 as against Rs 584.69 crore during the previous year ended March 2024. Sales rose 9.28% to Rs 3723.49 crore in the year ended March 2025 as against Rs 3407.25 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales966.08910.87 6 3723.493407.25 9 OPM %34.2428.03 -31.4026.43 - PBDT369.62284.41 30 1310.541022.33 28 PBT354.90266.31 33 1243.75952.65 31 NP260.14193.08 35 919.06584.69 57 Powered by Capital Market - Live

GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 13 May 2025, inter alia, have recommended the final dividend of Rs 42 per equity Share (i.e. 420%) , subject to the approval of the shareholders.Powered by Capital Market - Live